• Akari Therapeutics published its annual report for the year ended Dec. 31, 2025, pivoting to next-generation antibody-drug conjugates built on proprietary payload toxins.
• AKTX-101 remained the lead program in preclinical development, targeting Trop2 across multiple solid tumor types.
• Legacy programs nomacopan and PAS-nomacopan stayed paused for internal development, with partnering pursued to advance them externally.
• PHP-303 also shifted to an external partnering strategy, with impairment tied to reprioritization and lack of a partner.
• Going-concern uncertainty flagged, with management pursuing additional funding via financings or strategic collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.